Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.Anti-Human C1q Antibody
Sheep Anti-Human Polyclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| FC, E, ID |
|---|---|
| Primary Accession | P02745 |
| Other Accession | P02746, P02747 |
| Reactivity | Human |
| Host | Sheep |
| Clonality | Polyclonal |
| Isotype | Polyclonal IgG |
| Calculated MW | 26017 Da |
| Purification | Antisera to human C1q were raised by repeated immunisation of sheep with highly purified antigen. Purified IgG was prepared from whole serum by ion exchange chromatography. |
|---|---|
| Immunogen | Human C1q, purified from plasma. |
| Shelf Life | 18 months from the date of despatch. |
| Gene ID | 712 |
| Other Names | Complement C1q subcomponent subunit A, C1QA |
| Target/Specificity | Sheep anti-Human C1q antibody recognizes human C1q, a sub-component of the C1 complement component. |
| Preservative & Stabilisers | 0.09% Sodium Azide; 0.1% EACA; 0.01% Benzamidine; 1mM EDTA0.09% Sodium Azide |
| Storage | Store at +4℃ or at -20 ℃. |
| Precautions | Anti-Human C1q Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abgent.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
References
1. Hwang, H.Y. et al. (2008) Highly specific inhibition of C1q globular-head binding to human IgG: a novel approach to control and regulate the classical complement pathway using an engineered single chain antibody variable fragment.Mol Immunol. 45: 2570-80. 2. Cragg, M.S. and Glennie, M.J. (2004) Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents.Blood. 103: 2738-43. 3. Sárvári, M. et al. (2003) Inhibition of C1q-beta-amyloid binding protects hippocampal cells against complement mediated toxicity.J Neuroimmunol. 137: 12-8. 4. Lewis, M.J. et al. (2008) The different effector function capabilities of the seven equine IgG subclasses have implications for vaccine strategies.Mol Immunol. 45: 818-27. 5. Yuste, J. et al. (2007) Serum amyloid P aids complement-mediated immunity to Streptococcus pneumoniae.PLoS Pathog. 3: 1208-19. 6. Tang, Z. et al. (2013) A human single-domain antibody elicits potent antitumor activity by targeting an epitope in mesothelin close to the cancer cell surface.Mol Cancer Ther. 12: 416-26. 7. John, M. et al. (2000) Nephrotic syndrome in a patient with IgA deficiency-associated mesangioproliferative glomerulonephritis.Pathology. 32 (1): 56-8.
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Ordering Information
Other Products
Shipping Information
